Abstract
The societal consequences of dementia disorders in general, and Alzheimer’s disease (AD) in particular, are among the most important issues when discussing the situation of the health and social sectors (1). Dementia is regarded by the Organization for Economic Cooperation and Development (OECD) as one of the most important health and social policy issues in its member states (2) and the World Health Organisation (WHO) has regarded dementia as one of the major reasons for disability (3). Our research group at the Karolinska Institute in Stockholm, Sweden, has estimated that today, there are about 25 million people in the world suffering from dementia (4). Dementia disorders are costly and, combined with an economic crisis in many public health-care systems, raise fundamental questions that are included in any health economical analysis. Since we also have drugs that influence the symptomatology and also resource utilization and costs, issues of cost-effectiveness are of great importance. The economic and social burden of dementia disorders, particularly AD, is therefore the focus of this chapter. However, it must be stated that there are several methodological issues that need to be highlighted (5).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Johnson, N.; Davis,T.; Bosanquet, N.: The epidemic of Alzheimer’s disease. How can we manage the costs? Pharmacoeconomics 2000; 18 (3): 215–223.
OECD: Policy issues in dementia care in OECD countries. OECD; Paris, 2002.
WHO: World Health Report, 1999. World Health Organization ( WHO ), Geneva, 1999.
Wimo, A.; Winblad, B.; Aguero-Torres, H.; von Strauss, E.: The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003; 17: 63–67.
Winblad, B. et al.: What are the costs to society and to individuals regarding diagnostic procedures and care of patients with dementia? Acta Neurol Scand Suppl 1996; 168: 101–104.
Jonsson, B. et al.: Cost of dementia. In: May, M.; Sartorius, N. (eds.): Dementia. WPA series evidence and experience in psychiatry. Wiley, London, 2000: 335–363.
Wimo, A. et al.: Evaluation of the resource utilisation and caregiver time in anti-dementia drug trials -a quantitative battery. In: Wimo, A. et al. (eds.): The health economis of dementia. Wiley, London, 1998.
Fratiglioni, L. et al.: Occurrence of dementia in advanced age: the study design of the Kungsholmen Project. Neuroepidemiology 1992; 11 (suppl 1): 29–36.
Folstein, M.F.; Folstein, S.E.; McHugh, P.R.: “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–198.
Wimo, A. et al.: Treatment of Alzheimer’s disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Disord 1997; 11: 191–200.
Wimo, A. et al.: Cost-utility analysis of group living in dementia care. Int J Technol Assess Health Care 1995; 11: 49–65.
Drummond, M.F. et al.: Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford, 1997.
Karlsson, G. et al.: Methodological issues in health economics of dementia. In: Wimo, A. et al. (eds.): Health economics of dementia. Wiley, London, 1998: 161–169.
Lindgren, B.: Costs of illness in Sweden 1964–1975. Liber, Lund, 1981.
Wimo, A.; Winblad, B.: Pharmacoeconomics of dementia: impact of cholineesterase inhibitors. In: Gauthier, S.; Cummings, J. (eds.): Alzheimer’s disease and related disorders, annual 2002. Martin Dunitz, London, 2002.
Ernst, R.L.; Hay, J.W.: The US economic and social costs of Alzheimer’s disease revisited. Am J Public Health 1994; 84: 1261–1264.
Smith, K.A.; Shah, A.: The prevalence and costs of psychiatric disorders and learning disabilities. Br J Psychiatry 1995; 166: 9–18.
Ostbye, T.; Crosse, E.: Net economic costs of dementia in Canada. Can Med Assoc J 1994; 151: 1457–1464.
Wimo, A. et al.: Cost of illness due to dementia in Sweden. Int J Geriatr Psychiatry 1997; 12: 857–861.
Schulenberg, J.; Schulenberg, I.: Cost of treatment and cost of care for Alzheimer’s disease in Germany. In: Wimo, A. et al. (eds.): The health economics of dementia. Wiley, London, 1998.
Koopmanschap, M.A. et al.: Costs of dementia in the Netherlands. In: Wimo, A. et al. (eds.): The health economics of dementia. Wiley, London, 1998.
Kronborg Andersen, C. et al.: The cost of dementia in Denmark: the Odense Study. Dement Geriatr Cogn Disord 1999; 10: 295–304.
Cavallo, M.C.; Fattore, G.: The economic and social burden of Alzheimer’s disease on families in the Lombardy region of Italy. Alzheimer Dis Assoc Disord 1997; 11: 184–190.
O’Shea, E.; O’Reilly, S.: The economic and social cost of dementia in Ireland. Int J Geriatr Psychiatry 2000; 15: 208–218.
Wimo, A.; Winblad, B.: Pharmacoeconomics of dementia: impact of cholineesterase inhibitors. In: Gauthier, S.; Cummings, J. (eds.): Alzheimer’s disease and related disorders, annual 2002. Martin Dunitz, London, 2002: 145–167.
Wimo, A.; Jonsson, L.: Demenssjukdomarnas samh llskostnader (The societal costs of dementia) (in Swedish). Socialstyrelsen ( National Board of Wealth and Health Care ), Stockholm, 2001.
Hux, M.J. et al.: Relation between severity of Alzheimer’s disease and costs of caring. CMAJ 1998; 159: 457–465.
Wimo, A.; Jonsson, L.; Winblad, B.: Social burden and pharmacoeconomics of vascular dementia. In: Erkinjuntti, T.; Gauthier, S. (eds.): Vascular cognitive impairment. Martin Dunitz, London, 2002: 629–639.
Olsen, 7.A.; Smith, R.D.: Theory versus practice: a review of “willingness-to-pay” in health and health care. Health Econ 2001; 10: 39–52.
Siegel, J.E. et al.: Guidelines for pharmacoeconomic studies. Recommendations from the Panel on Cost Effectiveness in Health and Medicine. Panel on Cost Effectiveness in Health and Medicine. Pharmacoeconomics 1997; 11: 159–168.
Winblad, B. et al.: Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonisation of Dementia Drug Guidelines. Alzheimer DisAssoc Disord 1997; 11 (suppl 3): 39–45.
Grafstrom, M. et al.: Health and social consequences for relatives of demented and non-demented elderly. A population-based study. J Clin Epidemiol 1992; 45: 861–870.
Janson, W.; Grafstrom, M.; Winblad, B.: Daughters and sons as caregivers for their demented and non-demented elderly parents. A part of a population-based study carried out in Sweden. Scand J Soc Med 1997; 25: 289–295.
Schulz, R.; Beach, S.R.: Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA 1999; 282: 2215–2219.
Wimo, A. et al.: Time spent on informal and formal care giving for persons with dementia in Sweden. Health Policy 2002; 61: 255–268.
Stommel, M.; Collins, C.E.; Given, B.A.: The costs of family contributions to the care of persons with dementia. Gerontologist 1994; 34: 199–205.
Clipp, E.C.; Moore, M.J.: Caregiver time use: an outcome measure in clinical trial research on Alzheimer’s disease. Clin Pharmacol Ther 1995; 58: 228–236.
Rice, D.P. et al.: The economic burden of Alzheimer’s disease care. Health Aff (Millwood) 1993; 12: 164–176.
Albert, S.M. et al.: Hourly care received by people with Alzheimer’s disease: results from an urban, community survey. Gerontologist 1998; 38: 704–714.
McDaid, D.: Estimating the costs of informal care for people with Alzheimer’s disease: methodological and practical challenges. Int J Geriatr Psychiatry 2001; 16: 400–405.
Challis, D. et al.: Dependency in older people recently admitted to care homes. Age Ageing 2000; 29: 255–260.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Wimo, A., Winblad, B. (2004). The Economic Burden of Alzheimer’s Disease and Dementia. In: Richter, R.W., Richter, B.Z. (eds) Alzheimer’s Disease. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-661-4_6
Download citation
DOI: https://doi.org/10.1007/978-1-59259-661-4_6
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-4485-9
Online ISBN: 978-1-59259-661-4
eBook Packages: Springer Book Archive